Genvec 10Q 2013 Q3 Quarterly report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended September 30, 2013

	or

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934

	For the transition period from to

Commission file number:

0-24469

	GenVec, Inc.
	(Exact name of registrant as specified in its charter)

Delaware		23-2705690
(State or other jurisdiction of		(IRS Employer Identification
incorporation or organization)		Number)

65 West Watkins Mill Road, Gaithersburg, Maryland	20878
(Address of principal executive offices)	(Zip Code)

240-632-0740

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yesx No¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yesx No¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

	Large accelerated filer¨		Accelerated filer¨
	Non-accelerated filer¨		Smaller reporting companyx
	(do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes¨ Nox

As of October 31, 2013, the Registrant had 13,678,285shares of common stock, $.001 par value, outstanding.

GENVEC, INC.
FORM 10-Q

TABLE OF CONTENTS

PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)	3
	Condensed Balance Sheets	3
	Condensed Statements of Operations and Comprehensive Loss	4
	Condensed Statements of Cash Flows	5
	Notes to Condensed Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	25
Item 4.	Mine Safety Disclosures	25
Item 5.	Other Information	25
Item 6.	Exhibits	25

SIGNATURES		26

	2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GENVEC, INC.

CONDENSED BALANCE SHEETS

(in thousands, except per share data)

	September 30,		December 31,
	2013		2012
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,970	$	4,150
Investments		2,131		11,105
Accounts receivable, net		264		947
Prepaid expenses and other		211		226
Total current assets		7,576		16,428
Property and equipment, net		800		805
Other assets		281		197
Total assets	$	8,657	$	17,430

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,076	$	1,500
Accrued expenses and other		2,048		2,187
Total current liabilities		3,124		3,687

Commitments (Note 7)		-		-

Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued and outstanding in 2013 and 2012		-		-
Common stock, $0.001 par value; 30,000 shares authorized; 13,678 and 12,948 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively		14		13
Additional paid-in capital		280,426		279,518
Accumulated other comprehensive loss		(14)		(27)
Accumulated deficit		(274,893)		(265,761)
Total stockholders' equity		5,533		13,743
Total liabilities and stockholders’ equity	$	8,657	$	17,430

See accompanying notes to unaudited condensed financial statements.

	3

GENVEC, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share data)
(Unaudited)

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012

Revenues from strategic alliances and research contracts	$	1,582	$	2,128	$	3,537	$	7,832

Operating expenses:
Research and development		1,619		3,380		5,350		11,284
General and administrative		2,926		2,799		7,335		7,475
Total operating expenses		4,545		6,179		12,685		18,759

Operating loss		(2,963)		(4,051)		(9,148)		(10,927)

Other income:
Interest and Other Income, net		2		12		16		31

Net loss	$	(2,961)	$	(4,039)	$	(9,132)	$	(10,896)

Basic and diluted net loss per share	$	(0.23)	$	(0.31)	$	(0.71)	$	(0.84)

Shares used in computation of basic and diluted net loss per share		12,948		12,938		12,948		12,938

Comprehensive Loss:

Net loss	$	(2,961)	$	(4,039)	$	(9,132)	$	(10,896)

Unrealized holding gain/(loss) on securities available for sale		(6)		18		13		(1)

Comprehensive loss	$	(2,967)	$	(4,021)	$	(9,119)	$	(10,897)

See accompanying notes to unaudited condensed financial statements.

	4

GENVEC, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)

(Unaudited)

	Nine Months Ended
	September 30,
	2013		2012
Cash flows from operating activities:
Net loss	$	(9,132)	$	(10,896)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		139		181
Non-cash charges for stock-based compensation		909		950
Impairment of long lived assets		229		-
Changes in current assets and liabilities, net		135		1,846
Changes in non-current assets, net		(84)		(64)
Net cash used in operating activities		(7,804)		(7,983)

Cash flows from investing activities:
Purchases of property and equipment		(363)		(266)
Purchases of investment securities		(2,313)		(25,928)
Proceeds from sale and maturities of investment securities		11,300		35,035
Net cash provided by investing activities		8,624		8,841

Cash flows from financing activities		-		-

Increase in cash and cash equivalents		820		858
Beginning balance of cash and cash equivalents		4,150		4,114

Ending balance of cash and cash equivalents	$	4,970	$	4,972

See accompanying notes to unaudited condensed financial statements.

	5

GENVEC, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

(1)

General

Basis of Presentation

The condensed financial statements included herein have been prepared by GenVec, Inc. (GenVec, we, our, or the Company) without audit pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. We believe the disclosures are adequate to make the information presented not misleading. The condensed financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2012 Annual Report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of September 30, 2013 and December 31, 2012, the results of its operations for the three-month and nine-month periods ended September 30, 2013 and September 30, 2012, and cash flows for the nine-month periods ended September 30, 2013 and September 30, 2012. The results of operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

Business

GenVec is a biopharmaceutical company working with leading companies and organizations such as Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and the U.S. Government to leverage GenVec’s proprietary gene-delivery technologies to address the prevention and treatment of significant health concerns. GenVec’s lead program, in the field of regenerative medicine and licensed toNovartis, is for the development of novel treatments for hearing loss and balance disorders. We anticipate that Novartis will initiate a phase 1 clinical trial in 2014.

Key components of our strategy moving forward include:

	·	Working with Novartis to facilitate the development of first-in-class products for the treatment of hearing and balance disorders;
	·	Developing a sustainable revenue base by licensingrights toour proprietary vector and cell line technologies to additional companies and organizations;
	·	Licensing our pre-clinical vaccine candidates for the prevention of RSV and the treatment of HSV-2 infection; and
	·	Minimizing our cash burn by operating our business in a cost-efficient manner.

Our core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body.

Our research and development activities have been focused on identifying product candidates that utilize our technology platform and represent potential commercial opportunities. For example, preclinical research in hearing loss and balance disorders has indicated that the delivery of the atonal gene using GenVec’s adenovector technology may have the potential to restore hearing and balance function. We are working with Novartis on the discovery and development of novel treatments for hearing loss and balance disorders. There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem.

	6

Recent Events

Our current operating strategy was adopted on September 4, 2013, when we announced that our Board of Directors withdrew a Plan of Complete Liquidation and Dissolution of the Company (the Plan of Dissolution) that had been adopted by the Board of Directors on May 24, 2013, subject to stockholder approval. After announcing the approval of the Plan of Dissolution by the Board of Directors, the Company received several proposals for transactions with the Company, including transactions to purchase all or portions of the Company's assets or to engage in mergers with private companies that were looking to use the Company principally as a means to become publicly traded. As part of the Board of Directors' efforts to seek to maximize the value for stockholders and to provide stockholders with appropriate information for their consideration, the Board of Directors considered these proposals. Given that it was considering these proposals, the Board of Directors also authorized Cannacord Genuity Inc., an investment banking firm, to solicit additional proposals for the acquisition of our assets, and on June 24, 2013, the Company announced publicly that it had received and was considering proposals. The Board of Directors viewed the ability of the counterparties to complete the proposed transactions, in a timely manner, if at all, as extremely risky, the prospects for preserving value as very uncertain and the likelihood of receiving significant consideration in an asset sale as unlikely. The process that the Company went through in evaluating alternative proposals, the business developments during that time, the challenges in monetizing the Company's assets in the near term for values the Board of Directors thought would be fair, and the time that the process took, led the Board of Directors to conclude on September 4, 2013 that it was in the best interests of the Company's stockholders to withdraw the Plan of Dissolution and pursue the Company's current operating strategy.

In going through the process of considering the Plan of Dissolution and alternative transactions, we worked to terminate or further curtail a number of our contractual obligations and a significant portion of our operations. We also ceased to support some programs at the levels at which they were previously supported, or at all. On July 29, 2013, for example, we entered into a modification with the U.S. Naval Medical Logistics Command to terminate contractual obligations under our agreement related to dengue fever and malaria vaccine development efforts at the U.S. Naval Medical Research Center. In furtherance of these efforts, we announced on June 28, 2013, that we had terminated the employment of 30 of our then remaining 41 employees, and as of the date of this Quarterly Report on Form 10-Q we have 9 employees.

Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the success of our collaboration with Novartis and our success in entering into other licensing or collaboration transactions. Based on our current business operations, we estimate we have sufficient resources to fund our operations through at least the end of 2014.

Use of Estimates

The preparation of financial statements, in conformity with U.S. generally accepted accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities on the date of the financial statements, and revenues and expenses during the period. Critical accounting estimates involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate was made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period and would have a material impact on the presentation of our financial condition, results of operations, or cash flows. Our most critical accounting estimates relate to accounting policies for strategic alliance and research contract revenues, clinical trial expenses and research and development activities, and stock-based arrangements. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates.

	7

Revenue Recognition

Revenue is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and determinable, (iii) delivery of the services or products has occurred, and (iv) collectability of the contract amounts is considered probable.

Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments. Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis. Non-refundable research and development fees for which no future performance obligations exist are recognized when collection is assured. Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement. Determination of whether a milestone meets the aforementioned conditions involves the judgment of management.

Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels. Payments received in advance of work performed are recorded as deferred revenue.

Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received. During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations in the period in which such losses are determined.

Recent Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02,Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (Topic 220). The standard requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. The Company’s adoption of the provisions of this guidance on January 1, 2013 did not have a material impact on our financial position, results of operations, or cash flows.

There were no other new pronouncements effective as of September 30, 2013 that had a material effect on our financial position, results of operations, or cash flows. Additionally, other new pronouncements issued but not effective until after September 30, 2013 are not expected to have a material effect on our financial position, results of operations, or cash flows.

	8

Reclassifications

Certain reclassifications have been made to prior period amounts to conform to our current period presentation. Such reclassifications have no effect on net loss as previously reported.

(2)

Fair Value Measurements

For assets and liabilities measured at fair value we utilize FASB Accounting Standards Codification (ASC) Section 820 “Fair Value Measurements and Disclosures” (ASC 820) which defines fair value and establishes a framework for fair value measurements. This standard establishes a three-level hierarchy for disclosure of fair value measurements. The hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels of inputs used to measure fair value are as follows:

⋅	Level 1 – Quoted prices in active markets for identical assets or liabilities;

⋅	Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable (e.g., interest rates, yield curves, volatilities and default rates, among others) or that can be corroborated by observable market data; and

⋅	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.

The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet as of September 30, 2013:

			Quoted Prices in
			Active Markets for		Significant
	Total Carrying		Identical		Other Observable
	Value on the		Assets/Liabilities		Inputs
(In thousands)	Balance Sheet		(Level 1)		(Level 2)
Assets:
Cash and cash equivalents	$	4,970	$	4,970	$	-
Corporate notes and bonds		654		-		654
U.S. Government and agency securities		1,419		-		1,419
Equity security		58		58		-
Total assets at fair value	$	7,101	$	5,028	$	2,073

	9

The following table presents information about assets and liabilities recorded at fair value on a recurring basis as of December 31, 2012 on the Condensed Balance Sheet:

			Quoted Prices in
			Active Markets for		Significant
	Total Carrying		Identical		Other Observable
	Value on the		Assets/Liabilities		Inputs
(In thousands)	Balance Sheet		(Level 1)		(Level 2)
Assets:

Cash and cash equivalents	$	4,150	$	4,150	$	-
Corporate notes and bonds		6,871		-		6,871
U.S. Government and agency securities		4,189		-		4,189
Equity security		45		45		-
Total assets at fair value	$	15,255	$	4,195	$	11,060

We determine fair value for marketable securities with Level 1 inputs through quoted market prices and have classified them as available-for-sale. Our Level 2 marketable securities consist of corporate and U.S. agency bonds with maturities of less than 12 months.

We review all investments for other-than-temporary impairment at least quarterly or as indicators of impairment exist. Indicators of impairment include the duration and severity of the decline in fair value as well as the intent and ability to hold the investment to allow for a recovery in the market value of the investment. In addition, we consider qualitative factors that include: (i) the financial condition and business plans of the investee, including its future earnings potential; (ii) the investee’s credit rating; and (iii) the current and expected market and industry conditions in which the investee operates. If a decline in the fair value of an investment is deemed by management to be other-than-temporary, we write down the cost basis of the investment to fair value, and the amount of the write-down is included in net earnings. Such a determination is dependent on the facts and circumstances relating to each investment. We have determined there have been no such impairments in 2013 or 2012.

All unrealized holding gains or losses related to our investments in marketable securities are reflected in accumulated other comprehensive loss in stockholders’ equity. The change in accumulated other comprehensive loss was a net unrealized gain of $13,000 and a net unrealized loss of $1,000 for the nine months ended September 30, 2013 and September 30, 2012, respectively.

(3)

Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense related to employee stock options for the three-month and nine-month periods ended September 30, 2013 and September 30, 2012, which was allocated as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
	(in thousands)				(in thousands)

Research and development	$	83	$	208	$	503	$	636
General and administrative		200		104		406		314
	$	283	$	312	$	909	$	950

	10

We use the Black-Scholes pricing model to value stock options. The estimated fair value of employee stock options granted during the nine months ended September 30, 2013 and 2012 was calculated using the Black-Scholes model with the following weighted-average assumptions:

	For the Nine			For the Nine
	Months Ended			Months Ended
	September 30, 2013			September 30, 2012

Risk-free interest rate		1.05	%		1.04	%
Expected dividend yield		0.00	%		0.00	%
Expected volatility		98.09	%		97.97	%
Expected life (years)		6.20			6.34
Weighted-average fair value of options granted	$	1.22		$	2.00

The risk-free interest rate assumptions are based upon various U.S. Treasury rates as of the date of the grants,1.00% to2.63%, for the nine months ended September 30, 2013 and0.81% to1.58% for the nine months ended September 30, 2012.

The expected dividend yield is based on the assumption that we do not expect to declare a dividend over the life of the options.

The expected volatility assumptions for 2013 and 2012 are based on the weighted average volatility for the most recent one-year period as well as the volatility over the expected life of6.20 years and6.34 years, respectively.

The expected life of employee stock options represents the weighted average combining the actual life of options that have already been exercised or cancelled with the expected life of all outstanding options. The expected life of outstanding options is calculated assuming the options will be exercised in part at the midpoint of the vesting date (four years) and in part at the full contractual term (ten years).

The Company estimates forfeiture rates at the time of grant and revises these estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the demographics of current option holders and standard probabilities of employee turnover. We do not record tax-related effects on stock-based compensation given our historical and anticipated operating experience and offsetting changes in our valuation allowance, which fully reserves against potential deferred tax assets.

	11

Stock Options

The following table summarizes the stock option activity for the nine months ended September 30, 2013:

			Weighted		Weighted
			average		average		Aggregate
	Number		exercise		contractual		intrinsic
(in thousands,	of shares		price		life (years)		value
except exercise price and contractual term data)

Stock options outstanding, December 31, 2012		1,409	$	7.06
Granted		646		1.57
Forfeited		(549)		2.29
Expired		(183)		13.27
Stock options outstanding at September 30, 2013		1,323	$	5.50		7.72	$	9
Vested or expected to vest at September 30, 2013		1,258	$	5.68		7.65	$	9
Exercisable at September 30, 2013		908	$	6.97		7.19	$	-

Unrecognized stock-based compensation related to stock options was approximately $0.7 million as of September 30, 2013. This amount is expected to be expensed over a weighted average period of2.35 years. There were no options exercised during the nine months ended September 30, 2013 or 2012.

The following table summarizes information about our stock options outstanding as of September 30, 2013:

	Outstanding						Exercisable
			Weighted
			average		Weighted				Weighted
			remaining		average				average
Range of exercise	Number		contractual		exercise		Number		exercise
prices	of shares		life (in years)		price		of shares		price
	(number of shares in thousands)

$0.00 - $10.00		1,100		8.50	$	2.55		689	$	2.84
$10.01 - $20.00		124		3.41		15.82		124		15.82
$20.01 - $30.00		83		5.19		23.58		79		23.66
$30.01 - $41.25		16		0.84		33.68		16		33.68
		1,323		7.72	$	5.50		908	$	6.97

	12

Restricted Stock Awards

On September 3, 2013, the Company issued 730,000 restricted stock awards. The awards have a two-year vesting period and the fair value of the stock on the grant date was $0.266 per share. The following table summarizes the status of the Company’s non-vested restricted stock as of September 30, 2013:

			Weighted
			Average
	Number		Grant Date		Aggregate
(in thousands, except per share data)	of Units		Fair Value		Value

Non-vested restricted stock at December 31, 2012		-	$	-
Granted		730		0.27
Exercised		-		-
Cancelled		-		-

Non-vested restricted stock at September 30, 2013		730	$	0.27	$	194

Expected to vest at September 30, 2013		563	$	0.27	$	150

Restricted stock awards granted are scheduled to vest two years after the date of grant. The cost of each award is charged to operations over the vesting period. On September 30, 2013, the weighted average remaining term of non-vested restricted stock was1.9 years.

Forfeitures are estimated based on our historical forfeiture rates and standard probabilities of employee turnover based on the demographics of current option holders.

Unrecognized stock-based compensation related to restricted stock awards was approximately $188,000 as of September 30, 2013. This amount is expected to be expensed over a period of 1.9 years.

(4)

Net Loss per Share

Basic earnings per share is computed based upon the net loss available to common stock stockholders divided by the weighted average number of common stock shares outstanding during the period. The dilutive effect of common stock equivalents is included in the calculation of diluted earnings per share only when the effect of the inclusion would be dilutive. For the nine months ended September 30, 2013 and 2012, approximately1.9 million and1.6 millioncommon stock equivalent shares associated with our stock option plans and unvested restricted shares, respectively, and approximately1.3 million and1.4 million common stock equivalent shares associated with our warrants, respectively, were excluded from the denominator in the diluted loss per share calculation, as their inclusion would have been antidilutive due to our net loss incurred during the periods presented.

	13

(5)

Stockholders’ Equity

The table below sets forth the outstanding warrants to purchase shares of common stock as of September 30, 2013:

Offering Date

Outstanding Warrants

Exercise Price

Expiration Date

Status

May 2009

711,539

8.58

5/29/2014

Exercisable

February 2010

420,000

27.5

2/1/2015

Exercisable

1,131,539

On June 11, 2013,220,383 warrants with an exercise price of $20.16 issued in June 2008 expired. There were no warrants exercised during the nine months ended September 30, 2013.

(6)

Collaborative Agreements

In January 2010, we signed a research collaboration and license agreement (the Agreement) with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the Agreement, we licensed the world-wide rights to our preclinical hearing loss and balance disorders program. The Agreement was extended in January 2012 and again in January 2013. Under the extensions, Novartis will fund research at GenVec through January 2014 to support the preclinical hearing loss and balance disorders program. When the Agreement was executed in January 2010, we received a $5.0 million non-refundable upfront license fee and Novartis purchased $2.0 million of our common stock. The common stock was recorded at fair value of $3.3 million on the date of issuance. The non-refundable upfront license fee was recognized ratably over the original two-year research and collaboration term of the Agreement.Due to the pricing agreement associated with the sale of our common stock, revenue recognized from the non-refundable upfront license fee was $3.7 million by the end of the initial Agreement, as extended, in January 2014. In addition, we will receive funding from Novartis for a research program focused on developing additional adenovectors for hearing loss. No revenue from the upfront license fee was recognizedduring the three months ended September 30, 2013 or 2012. There was $47,000 and $152,000 of revenue recognized for research performed under the Agreement for the three months ended September 30, 2013 and 2012, respectively. During the nine months ended September 30, 2013 and 2012 we recognized $0 and $78,000, respectively, of the upfront payment and $299,000 and $581,000, respectively, for research performed under the Agreement.

Under the Agreement, we are eligible to receive milestones payments of up to $206.6 million, including up to $0.6 million for the achievement of preclinical development activities, up to $26.0 million for the achievement of clinical milestones (including non-rejection of an investigational new drug with respect to a covered product, the first patient visit in Phase I, Phase IIb, and Phase III clinical trials), up to $45.0 million for the receipt of regulatory approvals and up to $135.0 million for sales milestones. We have recognized $600,000 of milestone payments as a result of the successful completion of preclinical development activities prior to 2012. There were no milestones achieved in 2012 or during the nine months ended September 30, 2013.

In August 2010, we signed an agreement with Novartis for the supply of services relating to development materials in connection with the companies’ collaboration on the hearing loss and balance disorders program. Under this agreement, GenVec could receive approximately $13.0 million over four years to manufacture clinical trial material for up totwo lead candidates.During the three months ended September 30, 2013 and 2012 we recognized $35,000 and $0.9 million, respectively, for services performed under this agreement. During the nine months ended September 30, 2013 and 2012 we recognized $0.4 million and $3.0 million, respectively, for services performed under this agreement.

	14

In September 2012, we signed an agreement worth approximately $3.5 million with the U.S. Naval Medical Logistics Command to supportdengue fever andmalaria vaccine development efforts at the U.S. Naval Medical Research Center (NMRC). Under the terms of the agreement, GenVec was responsible for producing clinical supplies of its malaria vaccine, which utilizes its novel, proprietary technology. NMRC used the clinical material as part of its efforts to assess the safety and efficacy of these next-generation vectored vaccines using the clinical challenge model developed by NMRC and the Walter Reed Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the U.S. Military Malaria Vaccine Program (USMMVP). Under the agreement, GenVec retained the right to commercialize this novel technology. There was $1.4 million of revenue recognized under this contract during the three and nine-months ended September 30, 2013. On July 29, 2013, the Company entered into a termination agreement with the U.S. Naval Medical Logistics Command to terminate the September 2012agreement. That agreement was terminated pursuant to the Navy’s right of termination for convenience effective July 30, 2013 and was the result of a request by the Company, in light of the Company’s efforts to reduce its ongoing business operations. The Company received approximately $1.4 million of the $3.5 million that the Company originally anticipated receiving over athree-year period pursuant to the September 2012 agreement.

In April 2013, the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) announced that it would stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who later became infected with HIV. The HVTN 505 trial was designed to test the safety and efficacy of a two-part HIV vaccine regimen consisting of one vaccine designed to prime the immune system followed by another vaccine designed to boost the immune response. GenVec manufactured the adenovirus vector component utilized as the boost vaccine for this trial.

(7)

Litigation

On February 3, 2012, a putative class action lawsuit captionedSatish Shah v. GenVec, Inc., et al. Civil Action. No. 8:12 CV-00341-DKC was commenced in the United States District Court for the District of Maryland against the Company, Paul H. Fischer, Douglas J. Swirsky, and Mark O. Thornton. Following appointment of a Lead Plaintiff group in April 2012, Lead Plaintiffs filed a pleading titled Amended Class Action Complaint for Violations of the Federal Securities Laws on July 6, 2012 (the Amended Complaint). In the Amended Complaint, Lead Plaintiffs asserted claims, purportedly on behalf of a class of persons who had purchased or acquired Company common stock between March 12, 2009 and March 30, 2010 (the Class Period), that the Company and the individual defendants had violated Section 10(b) of the Securities Exchange Act of 1934 (the Exchange Act), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. Lead Plaintiffs alleged generally that defendants had made materially false or misleading statements or omissions concerning the prospects for the Company’s leading product candidate at the time, TNFerade, and the outcome of the then-ongoing clinical trial for TNFerade. Lead Plaintiffs alleged that these misrepresentations resulted in the Company’s common stock trading at artificially inflated prices throughout the Class Period. Lead Plaintiffs sought unspecified damages. On September 4, 2012, the Company and the individual defendants moved to dismiss the Amended Complaint in its entirety for failure to state a claim upon which relief can be granted. On September 20, 2013, the Court granted this motion and dismissed the case in its entirety and with prejudice. Lead Plaintiffs did not file an appeal.

On March 12, 2012, a putative shareholder derivative action was commenced in the United States District Court for the District of Maryland against certain current and former members of our Board of Directors and the Company as a nominal defendant. The case is styledGarnitschnig v. Horovitz, et al.and generally arose out of the matters alleged to underlie the securities action. The plaintiff, who purported to bring the action derivatively on behalf of the Company, alleged that the defendants violated their fiduciary duties, wasted corporate assets, and were unjustly enriched by the receipt of compensation while serving as our directors. More particularly, the plaintiff’s Complaint alleged that as a result of the defendants’ failure of oversight, we disseminated misleading public statements and improperly continued with a clinical trial. While theGarnitschnig action did not seek a monetary recovery against the Company, plaintiff sought, among other things, an unspecified award of damages against the defendants, an order directing us to make certain changes to our corporate governance and oversight procedures, disgorgement by the defendants of compensation and an award of attorneys’ fees. Pursuant to the Court’s order dated April 5, 2013, theGarnitschnig case was stayed pending a decision on the motions to dismiss filed in theShah action. On October 2, 2013, the parties entered into a stipulation confirming that the stay of theGarnitschnig action was lifted and providing that, if the plaintiff elected to continue with the action, he would file an Amended Complaint on or before November 26, 2013.

	15

On November 1, 2013, the plaintiff in theGarnitschnig action filed an Amended Verified Shareholder Derivative and Class Action Complaint (the “Amended Complaint”) that supersedes the previous Complaint and now asserts claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets and alleged violations of the duty of candor.The plaintiff, who purports to bring the Amended Complaint both derivatively and as a shareholder class action, alleges that certain current and former members of the Board of Directors exceeded their authority under the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) by exceeding certain limits applicable to both stock options and restricted stock. The Amended Complaint further alleges that Company’s Proxy Statement is materially false and misleading for failing to disclose the alleged violations of the 2011 Plan.The Complaint seeks both monetary relief and an injunction prohibiting the scheduled annual stockholders’ meeting of the Company until after corrective disclosures are provided to stockholders.The plaintiff in theGarnitschnig action also filed a motion for preliminary injunction at the same time that the Amended Complaint was filed. No hearing has been scheduled on this motion and Defendants have not yet filed any response.The Company intends to vigorously defend this action.

We also are informed that defendants deny the material allegations of theGarnitschnigaction and intend to continue vigorously defending the case.

Given the inherent uncertainties of the litigation, the ultimate outcome oftheGarnitschnig mattercannot be predicted at this time, nor can the amount of possible loss or range of loss, if any, be reasonably estimated. The Company does not believe that, based on currently available information, the outcome of this proceeding will have a material adverse effect on our financial condition.

(8)

Restructuring

On February 7, 2013, we eliminated nine positions as part of our efforts to lower operating costs to conserve capital. The Company incurred $175,000 of expenses due to the position eliminations with approximately $85,000 paid in the first quarter of 2013 and $90,000 in the second quarter of 2013.

On June 28, 2013, we announced the termination of 30 of our then-remaining 41 employees. The Company incurred $304,000 of expenses in the second quarter due to the position eliminations, which resulted in cash expenditures of that amount in the third quarter.

On September 3, 2013, we announced that Cynthia Collins, our then President and Chief Executive Officer, had departed the Company and resigned as a member of its Board of Directors. Douglas J. Swirsky, who had served asGenVec’s Senior Vice President and Chief Financial Officer since 2006, has been named as theCompany’s President and Chief Executive Officer and has been appointed to theCompany’s Board of Directors. The Company incurred $1.0 million of expense in the third quarter due to the departure of Ms. Collinsthat will be paid out over 18 months, in accordance with her employment agreement.

Additionally we have evaluated certain of our long-lived assets and determined that approximately $229,000 of these assets have been impaired during the second quarter of 2013.

Costs associated with the elimination of positions have been recorded as a general and administrative personnel cost. Costs associated with the impairment of long-lived assets have been recorded as a general and administrative loss on long-lived assets.

	16

GENVEC, INC.

FORM 10-Q

FORWARD-LOOKING STATEMENTS

ThisQuarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements and are based on management’s estimates, assumptions, and projections that are subject to risks and uncertainties. These statements can generally be identified by the use of forward-looking words like “believe,” “expect,” “intend,” “may,” “will,” “should,” “anticipate,” “estimate,” or similar terminology.

Although we believe that the expectations reflected in our forward-looking statements are reasonable as of the date we make them, actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to:

•	decisions we make with respect to the future and strategic direction of our Company;

•	the uncertainties regarding our long-term stability and plans raised by our adoption and then abandonment of a Plan of Complete Liquidation and Dissolution of the Company;

•	our product candidates being in the early stages of development;

•	our ability to find collaborators and the terms of our agreements that we may enter into with them;

•	our reliance on collaborators;

•	uncertainties with, and unexpected results and related analyses relating to, pre-clinical development and clinical trials of our product candidates;

•	the timing and content of future FDA regulatory actions related to us, our product candidates, or our collaborators;

•	our financial condition and the sufficiency of our existing cash, cash equivalents, marketable securities, and cash generated from operations and our ability to lower our operating costs; and

•	the scope and validity of patent protection for our product candidates and our ability to commercialize products without infringing the patent rights of others.

Further information on the factors and risks that could affect our business, financial condition, and results of operations is set forth under Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2012 and is contained in our other filings with the SEC. The filings are available on our website at www.genvec.com or at the SEC’s website, www.sec.gov.

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q, and we assume no duty to update our forward-looking statements.

	17

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

GenVec, Inc. (GenVec, we, our or the Company) is a biopharmaceutical company working with leading companies and organizations such as Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and the U.S. Government to leverage GenVec’s proprietary gene-delivery technologies to address the prevention and treatment of significant health concerns. GenVec’s lead program, in the field of regenerative medicine and licensed toNovartis, is for the development of novel treatments for hearing loss and balance disorders. We anticipate that Novartis will initiate a phase 1 clinical trial in 2014.

Key components of our strategy moving forward include:

	·	Working with Novartis to facilitate the development of first-in-class products for the treatment of hearing and balance disorders;
	·	Developing a sustainable revenue base by licensing rights to our proprietary vector and cell line technologies to additional companies and organizations;
	·	Licensing our pre-clinical vaccine candidates for the prevention of RSV and the treatment of HSV-2 infection; and
	·	Minimizing our cash burn by operating our business in a cost-efficient manner.

Recent Events

Our current operating strategy was adopted on September 4, 2013, when weannounced that our Board of Directors withdrew aPlan of Complete Liquidation and Dissolution of the Company (the “Plan of Dissolution”) that had been adopted by the Board of Directors on May 24, 2013, subject to stockholder approval. After announcing the approval of the Plan of Dissolution by the Board of Directors, the Company received several proposals for transactions with the Company, including transactions to purchase all or portions of the Company’s assets or to engage in mergers with private companies that were looking to use the Company principally as a means to become publicly traded. As part of the Board of Directors’ efforts to seek to maximize the value for stockholders and to provide stockholders with appropriate information for their consideration, the Board of Directors considered these proposals. Given that it was considering these proposals, the Board of Directors also authorized Cannacord Genuity Inc., an investment banking firm, to solicit additional proposals for the acquisition of our assets, and on June 24, 2013, the Company announced publicly that it had received and was considering proposals. The Board of Directors viewed the ability of the counterparties to complete the proposed transactions, in a timely manner, if at all, as extremely risky, the prospects for preserving value as very uncertain and the likelihood of receiving significant consideration in an asset sale as unlikely. The process that the Company went through in evaluating alternative proposals, the business developments during that time, the challenges in monetizing the Company’s assets in the near term for values the Board of Directors thought would be fair, and the time that the process took, led the Board of Directors to conclude on September 4, 2013 that it was in the best interests of the Company’s stockholders to withdraw the Plan of Dissolution and pursue the Company’s current operating strategy.

	18

In going through the process of considering the Plan of Dissolution and alternative transactions, we worked to terminate or further curtail a number of our contractual obligations and a significant portion of our operations. We also ceased to support some programs at the levels at which they were previously supported, or at all. On July 29, 2013, for example, we entered into a modification with the U.S. Naval Medical Logistics Command to terminate contractual obligations under our agreement related to dengue fever and malaria vaccine development efforts at the U.S. Naval Medical Research Center. In furtherance of these efforts, we announcedon June 28, 2013 that we had terminated the employment of 30 of our then remaining 41 employees, and as of the date of this Quarterly Report on Form 10-Q we have 9 employees.

Material risks and uncertainties relating to our business and our industry are described in Item 1A of Part II this Quarterly Report on Form 10-Q and in Item 1A of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The description of our business in this Form 10-Q should be read in conjunction with the information described in Item 1A of Part II of the Form 10-K for the fiscal year ended December 31, 2012.

FINANCIAL OVERVIEW FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2013 AND 2012

Results of Operations

GenVec’s net loss was $3.0 million (or $0.23 per share) on revenues of $1.6 million for the three months ended September 30, 2013. This compares to a net loss of $4.0 million (or $0.31 per share) on revenues of $2.1 million in the same period in the prior year. GenVec’s net loss was $9.1 million (or $0.71 per share) on revenues of $3.5 million for the nine months ended September 30, 2013. This compares to a net loss of $10.9 million (or $0.84 per share) on revenues of $7.8 million in the same period in the prior year. Included in our net loss for the first nine months of 2013 was stock-based compensation expense of $909,000, as compared to $950,000 for the same period in the prior year. GenVec ended the third quarter of 2013 with $7.1 million in cash, cash equivalents, and investments.

Revenue

Revenues for the three-month and nine-month periods ended September 30, 2013 were $1.6 million and $3.5 million, which represent decreases of 26% and 55%, respectively, as compared to $2.1 million and $7.8 million in the comparable prior year periods.

Revenues for the three-month and nine-month periods ended September 30, 2013 were derived from the collaboration with Novartis to discover and develop novel treatments for hearing loss and balance disorders and from the Company’s funded research and development programs with the Department of Homeland Security and National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), all of which use GenVec’s proprietary adenovector technology for the development of either vaccine candidates against foot-and-mouth disease (FMD) for livestock or vaccines against malaria, HIV, respiratory syncytial virus (RSV), and herpes simplex virus (HSV).

We entered into a research collaboration and license agreement (the Agreement) with Novartis in January 2010, which accounted for$47,000 and $152,000 of revenue for the three-month periods ended September 30, 2013 and 2012, respectively. For the nine-month periods ended September 30, 2013 and 2012, we recognized $299,000 and $581,000, respectively under the same agreement.

	19

In August 2010, the Company and Novartis entered into a development agreement related to the supply of clinical trial material in connection with activities under the Agreement, which accounted for$35,000 and $0.9 million in revenue for the three-month periods ended September 30, 2013 and 2012, respectively. During the nine-month periods ended September 30, 2013 and September 30, 2012, we recognized $0.4 million and $3.0 million, respectively, for services performed under this agreement.

In September 2012, we signed an agreement worth approximately $3.5 million with the U.S. Naval Medical Logistics Command to support dengue fever and malaria vaccine development efforts at the U.S. Naval Medical Research Center (NMRC). Under the terms of the agreement, GenVec was responsible for producing clinical supplies of its malaria vaccine, which utilizes its novel, proprietary technology. NMRC used this clinical material as part of its efforts to assess the safety and efficacy of these next-generation vectored vaccines using the clinical challenge model developed by NMRC and the Walter Reed Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the U.S. Military Malaria Vaccine Program (USMMVP). Under the agreement, GenVec retained the right to commercialize this novel technology. There was $1.4 million of revenue recognized under this contract during the three-month and nine-month periods ended September 30, 2013 and no revenue recognized under this contract during the three-month and nine-month periods ended September 30, 2012. On July 29, 2013, we entered into a modification to terminate contractual obligations under the agreement. Additionally, during both the three-month and nine-month periods ended September 30, 2013, the Company experienced reduced revenue associated with its malaria grant programs as compared to the comparable periods in 2012.

The decrease in revenue for the three-month and nine-month periods ended September 30, 2013 is primarily attributable to decreases of $0.9 million and $3.0 million, respectively associated with our hearing program. The decrease in revenue associated with our hearing program was a result of a reduced work scope as we near completion of our development work under the two Novartis agreements. Additionally, there were reductions in revenue with respect to our FMD program of $0.4 million during the three months ended September 30, 2013 and $1.2 million during the nine months ended September 30, 2013 compared to the comparable prior year periods due mainly to the successful completion of field safety studies in 2012. These revenue decreases were partially offset by a $1.3 million increase in revenue associated with our dengue fever and malaria program with the NMRC in both the three-month and nine-month periods ending September 30, 2013 as compared to the comparable prior year periods. On July 29, 2013, we entered into a modification to terminate contractual obligations under the NMRC agreement.

Revenues recognized under our various funded research projects for the three-month and nine-month periods ended September 30, 2013 and 2012 are as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012

Hearing loss and balance disorders	$	85	$	1,018	$	790	$	3,748
Animal Health		58		495		621		1,866
HIV		4		81		159		410
Malaria		1,423		97		1,567		308
Other		12		437		400		1,500

Total	$	1,582	$	2,128	$	3,537	$	7,832

Expenses

Operating expenses were $4.5 million and $12.7 million for the three months and nine months ended September 30, 2013, which represent decreases of 26% and 32%, respectively, as compared to $6.2 million and $18.8 million in the comparable prior year periods.

	20

Research and development expenses for the three months and nine months ended September 30, 2013 decreased 52% and 53%, respectively, from $3.4 million and $11.3 million in 2012 to $1.6 million and $5.4 million in 2013. During both the three and nine months ended September 30, 2013 we experienced lower personnel costs resulting from our position eliminations, reduced manufacturing costs associated with our FMD program, reduced material costs for our hearing program and lower general supply costs, and equipment purchases for our hearing program as compared to the comparable periods in 2012.

General and administrative expense for the three months and nine months ended September 30, 2013 increased 5% and decreased 2%, respectively, with expense of approximately $2.8 million and $7.5 million in 2012 as compared to $2.9 million and $7.3 million in 2013. During the three months ended September 30, 2013 we experienced higher personnel costs resulting from our position eliminations as compared to the comparable period in 2012. During the nine months ended September 30, 2012, we experienced higher personnel costs and higher recruiting costs resulting from our 2012 Chief Executive Officer search. Partially offsetting these reduced costs in 2013 are higher professional costs, including expenses incurred in connection with our consideration of the Plan of Dissolution and related transactions, and the impairment of certain of our long-lived assets. Included in general and administrative expenseduring the three and nine months ended September 30, 2013, are charges of$1.0 million and $1.5 million of severance costsrelated to the respectiveFebruary 7, 2013 and June 28, 2013 position eliminations, and the departure of our then Chief Executive Officer on September 3, 2013. Additionally we have evaluated certain of our long-lived assets and determined that approximately $229,000 of these assets have been impaired during the nine months ended September 30, 2013.

Liquidity and Capital Resources

We have experienced significant losses since our inception. As of September 30, 2013 we have an accumulated deficit of $274.9 million. The process of developing and commercializing our product candidates requires significant research and development work and clinical trial work, as well as significant manufacturing and process development efforts. These activities, together with our general and administrative expenses, are expected to continue to result in significant operating losses for the foreseeable future.

As of September 30, 2013, cash, cash equivalents, and investments totaled $7.1 million as compared to $15.3 million as of December 31, 2012.

For the nine months ended September 30, 2013, we used $7.8 million of cash for operating activities. This consisted of a net loss for the period of $9.1 million, $0.1 million of non-cash depreciation and amortization, $0.9 million of non-cash stock option expenses, $0.2 million of impaired long-lived assets, $0.1 million provided by the net change in current assets and liabilities; and $0.1 million used for the net change in non-current assets. Net cash used in operating activities was used primarily for our internally funded research and development programs and general and administrative activities.

For the nine months ended September 30, 2012, we used $8.0 million of cash for operating activities. This consisted of a net loss for the period of $10.9 million, $0.2 million of non-cash depreciation and amortization, $1.0 million of non-cash stock option expenses, $1.8 million provided by the net change in current assets and liabilities; and $0.1 million used for the net change in non-current assets. Net cash used in operating activities was used primarily for the advancement of our internally funded research and development programs and general and administrative activities.

Net cash provided by investing activities during the nine months ended September 30, 2013 was $8.6 million. This consisted of $0.4 million of cash used for the purchase of laboratory equipment and $2.3 million of cash used to purchase investment securities during the period offset by proceeds from the sale and maturities of investments of $11.3 million.

Net cash provided by investing activities during the nine months ended September 30, 2012 was $8.8 million. This consisted of $0.3 million of cash used for the purchase of laboratory equipment and $25.9 million of cash used to purchase investment securities during the period offset by proceeds from the sale and maturities of investments of $35.0 million.

There were no financing activities during the nine months ended September 30, 2013 or 2012.

	21

Historically we have entered into agreements with academic medical institutions and contract research organizations to perform research and development activities and with clinical sites for the treatment of patients under clinical protocols. Such contracts expire at various dates and have differing renewal and expiration clauses. We also utilize different financing instruments, such as operating leases, to finance various equipment and facility needs.

Since our initial public offering, we have raised capital by offering shares of our common stock and warrants to purchase shares of our common stock in a variety of offerings. As a result of a number of these offerings, as of October 31, 2013, we have approximately 1.1 million warrants outstanding. Please see Note 5 “Stockholders’ Equity” of the Notes to Financial Statements included in this Quarterly Report on Form 10-Q.

On September 7, 2011, we entered into a Stockholder Rights Agreement between the Company and American Stock Transfer & Trust Company, LLC, as rights agent. The Stockholder Rights Agreement was not adopted in response to any specific effort to acquire control of the Company. In connection with the adoption of the new Stockholder Rights Agreement, the Company’s Board of Directors declared a dividend of one preferred stock purchase right (Right) for each outstanding share of common stock to stockholders of record as of the close of business on September 7, 2011. Initially, the Rights will be represented by GenVec’s common stock certificates or book entry notations, will not be traded separately from the common stock, and will not be exercisable. In the event that any person acquires beneficial ownership of 20% or more of the outstanding shares of GenVec’s common stock, or upon the occurrence of certain other events, each holder of a Right, other than the acquirer, would be entitled to receive, upon payment of the purchase price, which is initially set at $32 per Right, a number of shares of GenVec common stock having a value equal to two times such purchase price. The Company’s Board of Directors is entitled to redeem the Rights at $0.001 per right at any time before a person or group has acquired 20% or more of the Company’s common stock. The Rights will expire on September 7, 2021, subject to the Company’s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated. The Rights will at no time have any voting rights. The Company has authorized 30,000 shares of Series B Junior Participating Preferred Stock in connection with the adoption of the new Stockholder Rights Agreement. There was no Series B Junior Participating Preferred Stock issued or outstanding as of September 30, 2013.

On June 25, 2013, we received a notice from The NASDAQ Stock Market LLC (NASDAQ) stating that the minimum bid price of our common stock had been below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule 5550(a)(2). The notification letter stated that we would be afforded 180 calendar days, or until December 23, 2013, to regain compliance with the minimum bid price requirement.On October 7, 2013, we received a letter from NASDAQ stating that the Company had regained compliance with the minimum bid price requirement because the closing bid price of our common stock had met or exceeded $1.00 per share for at least ten consecutive business days. The letter further stated that the matter relating to the Company’s non-compliance with the minimum bid price requirement had been closed with NASDAQ.

Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, licensing and commercialization activities. Based on our current business plan, we estimate we will use between $5 million and $6 million of cash during the next four quarters, ending September 30, 2014. Our estimate includes approximately $0.9 million in contractual obligations and limited capital expenditures. Based on this estimate we expect to have sufficient resources to fund our operations through at least the end of 2014.

Off-Balance Sheet Arrangements and Contractual Obligations

We have no off-balance sheet financing arrangements other than in connection with our operating leases, which are disclosed in Note 7,Commitments, of the Notes to Financial Statements included in Annual Report on Form 10-K for the year ended December 31, 2012.

	22

Significant Accounting Policies and Estimates

We describe our significant accounting policies in Note 2,Summary of Significant Accounting Policies, of the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012. We discuss our critical accounting estimates in Item 7,Management’s Discussion and Analysis of Financial Condition and Results of Operations, in our Annual Report on Form 10-K for the year ended December 31, 2012. There have been no material changes in our significant accounting policies or critical accounting estimates since the end of 2012, however Note 1,General, of the Notes to Financial Statements included in this Quarterly Report on Form 10-Q discusses the revenue recognition for fixed-price contracts.

Recently Issued Accounting Pronouncements

For a discussion of recently issued accounting pronouncements, refer to the section titled“Recent Accounting Pronouncements” within Note 1General in the notes to our Financial Statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

As of September 30, 2013, under the supervision and with the participation of our President and Chief Executive Officer, Chief Financial Officer, Treasurer, and Corporate Secretary (our principal executive officer and principal financial officer), we have reviewed and evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our President and Chief Executive Officer, Chief Financial Officer, Treasurer, and Corporate Secretary has concluded that, as of September 30, 2013, these disclosure controls and procedures are effective at the reasonable assurance level in alerting them in a timely manner to material information required to be included in our periodic SEC reports.

There were no changes in our internal controls over financial reporting during the quarter ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

	23

On November 1, 2013, the plaintiff in theGarnitschnig action filed an Amended Verified Shareholder Derivative and Class Action Complaint (the “Amended Complaint”) that supersedes the previous Complaint and now asserts claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets and alleged violations of the duty of candor. The plaintiff, who purports to bring the Amended Complaint both derivatively and as a shareholder class action, alleges that certain current and former members of the Board of Directors exceeded their authority under the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) by exceeding certain limits applicable to both stock options and restricted stock. The Amended Complaint further alleges that Company’s Proxy Statement is materially false and misleading for failing to disclose the alleged violations of the 2011 Plan. The Complaint seeks both monetary relief and an injunction prohibiting the scheduled annual stockholders’ meeting of the Company until after corrective disclosures are provided to stockholders. The plaintiff in theGarnitschnig action also filed a motion for preliminary injunction at the same time that the Amended Complaint was filed. No hearing has been scheduled on this motion and Defendants have not yet filed any response. The Company intends to vigorously defend this action.

We also are informed that defendants deny the material allegations of theGarnitschnigaction and intend to continue vigorously defending the case.

Given the inherent uncertainties of the litigation, the ultimate outcome of theGarnitschnig matter cannot be predicted at this time, nor can the amount of possible loss or range of loss, if any, be reasonably estimated. The Company does not believe that, based on currently available information, the outcome of this proceeding will have a material adverse effect on our financial condition.

ITEM 1A.

RISK FACTORS

Investing in our securities involves a high degree of risk. You should carefully consider the risk factor set forth below and the risk factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, as well as other information contained in the Annual Report, in this Quarterly Report on Form 10-Q and in the other reports we file with the SEC.

The Board of Directors has withdrawn our previously adopted Plan of Dissolution, and adopted a new operating strategy, and we do not know if it will be successful.

Our Board of Directors has determined to withdraw a previously approved Plan of Complete Liquidation and Dissolution of the Company (the Plan of Dissolution) and has approved an operating strategy focused on working with leading companies and organizations such as Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and the U.S. Government to leverage our proprietary gene-delivery technologies to address the prevention and treatment of significant health concerns. This strategy includes working with Novartis to facilitate the development of first-in-class products for the treatment of hearing and balance disorders, developing a sustainable revenue base by licensing rights to our proprietary vector and cell line technologies to additional companies and organizations, licensing our pre-clinical vaccine candidates for the prevention of RSV and the treatment of HSV-2 infection, and minimizing our cash burn by operating our business in a cost-efficient manner. This operating strategy may not be successful, and is largely dependent on the success of our collaboration agreement with Novartis, of which there can be no assurance. Furthermore, our ability to execute on our operating strategy may also be affected by our having approved and then withdrawn the Plan of Dissolution. For example, potential licensees or other collaborators may be reluctant to enter into arrangements with us on terms that are acceptable to us, or at all, because of any concerns regarding our long-term stability and plans raised by our adoption and then abandonment of the Plan of Dissolution. Accordingly, we may not be able to successfully execute our operating strategy.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

	24

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

None.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

	10.1		Amendment, dated July 29, 2013, of Agreement with the U.S. Naval Medical Logistics Command regarding malaria vaccine development for the U.S. Naval Medical Research Center, dated September 29, 2012. ⁺

	10.2		Amendment to the GenVec, Inc. 2011 Omnibus Incentive Plan.

	10.3		GenVec, Inc. 2011 Omnibus Incentive Plan.

	31.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	101.INS		XBRL Instance Document.

	101.SCH		XBRL Taxonomy Extension Schema Document.

	101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

	101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

	101.LAB		XBRL Taxonomy Extension Label Linkbase Document.

	101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

⁺	Certain portions of this exhibit have been omitted based upon a request for confidential treatment. The omitted portions have been filed with the Commission pursuant to our application for confidential treatment.

	25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		GENVEC, INC.
		(Registrant)

Date: November 12, 2013	By:	/s/ Douglas J. Swirsky
		Douglas J. Swirsky
		President and Chief Executive Officer,Chief
		Financial Officer, Treasurer, and Corporate Secretary

	26

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

Genvec (GNVC) Inactive 10-Q2013 Q3 Quarterly report

Content analysis